PLK1 and osteosarcoma: In order to exclude no-specific effects of inhibitor, we first investigated the role of PLK1 in SJSA-1 and 143B osteosarcoma cells by deleting PLK1 using two independent PLK1 sgRNAs from the kinome-wide CRISPR-Cas9 screens (Fig. 3A, B).